DMA® Oncology

DMA® provides crucial insights for early cancer detection and treatment monitoring. In early stages, tumors—benign or malignant—cause increased metabolism due to rapid cell proliferation in the affected organ.

DMA® measures the organ’s metabolic response to key markers: inflammatory (interleukins), oxidative (free radicals), proliferative (C-MYC, C-RAS), and catabolic (nitrogen waste, sugar/protein byproducts).

It can assess a specific organ or the whole body (Total-body-DMA®), offering a non-invasive way to detect primary tumors and track potential metastases.